Nayan Lamba1,2, Elie Mehanna3, Rachel B Kearney4, Paul J Catalano5, Paul D Brown6, Daphne A Haas-Kogan4, Ayal A Aizer4. 1. Department of Medicine, Cambridge Health Alliance, 1493 Cambridge Street, Cambridge, MA, 02139, USA. nlamba@partners.org. 2. Department of Radiation Oncology, Dana-Farber Cancer Institute, Brigham and Women's Hospital, Boston, MA, USA. nlamba@partners.org. 3. Harvard Medical School, Boston, MA, USA. 4. Department of Radiation Oncology, Dana-Farber Cancer Institute, Brigham and Women's Hospital, Boston, MA, USA. 5. Department of Biostatistics, Harvard T.H. Chan School of Public Health, and Department of Biostatistics and Computational Biology, Dana-Farber Cancer Institute, Boston, MA, USA. 6. Department of Radiation Oncology, Mayo Clinic, Rochester, MN, USA.
Abstract
PURPOSE: Whole brain radiation therapy (WBRT) remains an important component of treatment for patients with multiple brain metastases (BrM) but is associated with significant neurotoxicity and memory impairment. Although RTOG 0614 demonstrated that administration of memantine to patients receiving WBRT may reduce radiation-associated cognitive decline, prior literature has suggested that radiation oncologists are hesitant to prescribe memantine. We sought to assess the frequency of memantine prescription in patients managed with non-stereotactic, brain-directed radiation for BrM. METHODS: Patients > 65 years old with newly diagnosed BrM between 2007 and 2016 receiving non-stereotactic, brain-directed radiation (including WBRT) were identified using the SEER-Medicare database. Receipt of memantine with non-stereotactic, brain-directed radiation was defined as any Part D claim for memantine 30 days before or after initiation of non-stereotactic, brain-directed radiation. Clinical and demographic variables among patients who did and did not receive memantine were compared. RESULTS: Between 2007 and 2016, we identified 6220 patients with BrM receiving non-stereotactic, brain-directed radiation. Only 2.20% of patients (n = 137) received memantine with radiation. Rates were 1.10% versus 5.14% in the period preceding (2007-2013) and following (2014-2016) the publication of RTOG 0614, respectively. Overall utilization of memantine remained low across several clinical, demographic, and prognostic variables. CONCLUSION: Despite phase 3 evidence supporting memantine utilization among patients receiving WBRT, our population-based study indicates that rates of memantine prescription are strikingly low, although memantine utilization seems to be increasing since publication of RTOG 0614. Further investigation is needed to identify provider and practice-related barriers preventing incorporation of memantine into management paradigms.
PURPOSE: Whole brain radiation therapy (WBRT) remains an important component of treatment for patients with multiple brain metastases (BrM) but is associated with significant neurotoxicity and memory impairment. Although RTOG 0614 demonstrated that administration of memantine to patients receiving WBRT may reduce radiation-associated cognitive decline, prior literature has suggested that radiation oncologists are hesitant to prescribe memantine. We sought to assess the frequency of memantine prescription in patients managed with non-stereotactic, brain-directed radiation for BrM. METHODS:Patients > 65 years old with newly diagnosed BrM between 2007 and 2016 receiving non-stereotactic, brain-directed radiation (including WBRT) were identified using the SEER-Medicare database. Receipt of memantine with non-stereotactic, brain-directed radiation was defined as any Part D claim for memantine 30 days before or after initiation of non-stereotactic, brain-directed radiation. Clinical and demographic variables among patients who did and did not receive memantine were compared. RESULTS: Between 2007 and 2016, we identified 6220 patients with BrM receiving non-stereotactic, brain-directed radiation. Only 2.20% of patients (n = 137) received memantine with radiation. Rates were 1.10% versus 5.14% in the period preceding (2007-2013) and following (2014-2016) the publication of RTOG 0614, respectively. Overall utilization of memantine remained low across several clinical, demographic, and prognostic variables. CONCLUSION: Despite phase 3 evidence supporting memantine utilization among patients receiving WBRT, our population-based study indicates that rates of memantine prescription are strikingly low, although memantine utilization seems to be increasing since publication of RTOG 0614. Further investigation is needed to identify provider and practice-related barriers preventing incorporation of memantine into management paradigms.
Authors: Daniel N Cagney; Allison M Martin; Paul J Catalano; Paul D Brown; Brian M Alexander; Nancy U Lin; Ayal A Aizer Journal: JAMA Oncol Date: 2018-07-01 Impact factor: 31.777
Authors: Vinai Gondi; Stephanie L Pugh; Wolfgang A Tome; Chip Caine; Ben Corn; Andrew Kanner; Howard Rowley; Vijayananda Kundapur; Albert DeNittis; Jeffrey N Greenspoon; Andre A Konski; Glenn S Bauman; Sunjay Shah; Wenyin Shi; Merideth Wendland; Lisa Kachnic; Minesh P Mehta Journal: J Clin Oncol Date: 2014-10-27 Impact factor: 44.544
Authors: Paul D Brown; Stephanie Pugh; Nadia N Laack; Jeffrey S Wefel; Deepak Khuntia; Christina Meyers; Ali Choucair; Sherry Fox; John H Suh; David Roberge; Vivek Kavadi; Soren M Bentzen; Minesh P Mehta; Deborah Watkins-Bruner Journal: Neuro Oncol Date: 2013-08-16 Impact factor: 12.300
Authors: Paul D Brown; Karla V Ballman; Jane H Cerhan; S Keith Anderson; Xiomara W Carrero; Anthony C Whitton; Jeffrey Greenspoon; Ian F Parney; Nadia N I Laack; Jonathan B Ashman; Jean-Paul Bahary; Costas G Hadjipanayis; James J Urbanic; Fred G Barker; Elana Farace; Deepak Khuntia; Caterina Giannini; Jan C Buckner; Evanthia Galanis; David Roberge Journal: Lancet Oncol Date: 2017-07-04 Impact factor: 41.316
Authors: Riccardo Soffietti; Martin Kocher; Ufuk M Abacioglu; Salvador Villa; François Fauchon; Brigitta G Baumert; Laura Fariselli; Tzahala Tzuk-Shina; Rolf-Dieter Kortmann; Christian Carrie; Mohamed Ben Hassel; Mauri Kouri; Egils Valeinis; Dirk van den Berge; Rolf-Peter Mueller; Gloria Tridello; Laurence Collette; Andrew Bottomley Journal: J Clin Oncol Date: 2012-12-03 Impact factor: 44.544
Authors: Edward G Shaw; Robin Rosdhal; Ralph B D'Agostino; James Lovato; Michelle J Naughton; Michael E Robbins; Stephen R Rapp Journal: J Clin Oncol Date: 2006-03-20 Impact factor: 44.544
Authors: William A Hall; Stephanie L Pugh; Jeffrey S Wefel; Terri S Armstrong; Mark R Gilbert; David G Brachman; Maria Werner-Wasik; Merideth M Wendland; Paul D Brown; Samuel T Chao; Kevin S Roof; H Ian Robins; Minesh P Mehta; Walter J Curran; Benjamin Movsas Journal: Neurosurgery Date: 2019-01-01 Impact factor: 4.654
Authors: Eric L Chang; Jeffrey S Wefel; Kenneth R Hess; Pamela K Allen; Frederick F Lang; David G Kornguth; Rebecca B Arbuckle; J Michael Swint; Almon S Shiu; Moshe H Maor; Christina A Meyers Journal: Lancet Oncol Date: 2009-10-02 Impact factor: 41.316
Authors: Alyssa Y Li; Karolina Gaebe; Katarzyna J Jerzak; Parneet K Cheema; Arjun Sahgal; Sunit Das Journal: Front Oncol Date: 2022-03-07 Impact factor: 6.244